X
Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
Here are the latest stock price details of India's top Indian Pharma stocks. For more detailed updates, read our Indian Pharma sector report and check the latest Indian Pharma sector results.
| SCRIP | BSE PRICE (Rs) | NSE PRICE (Rs) | CHART | GET MORE INFO |
|---|---|---|---|---|
| AARTI DRUGS | 515.00 -1.01% | 514.90 -0.67% | More Info
|
|
| AJANTA PHARMA | 1,683.50 0.73% | 1,683.10 0.38% | More Info
|
|
| ALEMBIC PHARMA | 582.55 -1.76% | 584.35 -1.46% | More Info
|
|
| AUROBINDO PHARMA | 535.00 -1.30% | 534.50 -1.33% | More Info
|
|
| BIOCON LTD | 920.10 -2.80% | 919.70 -2.82% | More Info
|
|
| CADILA HEALTHCARE | 438.95 -0.50% | 438.20 -0.60% | More Info
|
|
| CIPLA | 529.90 -0.61% | 530.10 -0.58% | More Info
|
|
| DISHMAN PHARMA | 276.10 -2.46% | 275.80 -2.23% | More Info
|
|
| DIVIS LABORATORIES | 568.20 -1.39% | 568.20 -1.35% | More Info
|
|
| DR. REDDYS LAB | 2,544.05 -1.32% | 2,541.50 -1.47% | More Info
|
|
| ELDER PHARMA | 38.00 4.97% | 83.30 0.97% | More Info
|
|
| FRESENIUS KABI ONCO. | 132.45 0.26% | 788.85 0.44% | More Info
|
|
| GLENMARK PHARMA | 637.30 -2.09% | 636.45 -2.26% | More Info
|
|
| INDOCO REMEDIES | 193.60 -2.64% | 193.25 -2.87% | More Info
|
|
| IPCA LABS | 514.20 0.24% | 514.70 0.93% | More Info
|
|
| J.B.CHEMICALS | 337.30 -1.85% | 336.50 -2.25% | More Info
|
|
| LUPIN LTD | 1,253.25 0.34% | 1,253.50 0.23% | More Info
|
|
| NATCO PHARMA | 906.00 0.73% | 906.00 0.67% | More Info
|
|
| NIFTY 50 | Not Listed | 9,418.40 0.34% | More Info
|
|
| ORCHID PHARMA LTD | 29.70 0.17% | 29.70 0.00% | More Info
|
|
| PANACEA BIOTECH | 134.40 0.60% | 133.40 0.00% | More Info
|
|
| PIRAMAL ENTERPRISES | 2,700.45 -1.09% | 2,697.60 -1.10% | More Info
|
|
| S&P BSE SENSEX | 30,488.84 0.41% | Not Listed | More Info
|
|
| STRIDES SHASUN LTD | 903.80 -0.30% | 903.10 -0.48% | More Info
|
|
| SUN PHARMA | 612.45 -0.02% | 612.45 -0.27% | More Info
|
|
| TORRENT PHARMA | 1,249.60 -1.22% | 1,249.40 -1.12% | More Info
|
|
| WOCKHARDT LTD. | 616.80 -0.11% | 616.15 0.15% | More Info
|
BSE prices: May 24, 2017 11:39:00 AM NSE prices: May 24, 2017 11:40:00 AM
|
| |
Asian equity markets are lower today ahead of US Federal Reserve views on interest rate hike prospects and await an upcoming OPEC meeting.
Base price erosion in the US and lower Zetia sales impacts profits.
Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.
Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.
Equitymaster analyses Initial Public Offering (IPO) of Laurus Labs, one of the leading supplier of APIs for ARVs and Hepatitis C.
Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.
More Views on NewsThe manufacturing growth between December 2016 and March 2017 fell to 1.6 per cent as against 6.9 per cent between April and October 2016.
Apurva shows how a simple but effective pattern has helped him generate returns like 9.09%, 11.41%, and 17.89%.
A template that will help you identify the 'emphatic sells'.
Markets are at record highs. Fear is at record lows. How does this end? When does this end?
PersonalFN explains how a good robo-adviser can offer you a world of convenience.
More|
| |
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
